Teva Pharm (TEVA) Tops Q2 EPS by 1c
More News related to TEVA
- Teva Pharma (TEVA) Gets Final U.S. FDA Approval for Generic Prevacid
- Teva Receives Final Approval for Generic Prevacid(R) Delayed-Release Capsules
- Teva Pharma (TEVA) Announces Generic Version of Prevacid Does Not Infringe on Patents
- Teva Receives Favorable Court Decision Regarding Generic Prevacid(R) SoluTab
- Teva Pharma (TEVA) Seeks to Amend Existing Complaint Against Momenta Pharma over Copaxone Patent Infringement
More News related to Earnings
- Communications Systems (JCS) Reports Year-Over-Year Decline in Q3 Earnings
- Communications Systems (JCS) Posts Q3 EPS of $0.22, Down Y/Y
- Atmos Energy (ATO) Posts Q4 Loss of $0.17, Wider than Estimates
- China Digital TV (STV) Misses Q3 EPS by 2c; Guides Below for Q4
- Ralcorp (RAH) Misses Street's Q4 Views; Announces 7M Share Buyback
Teva Pharm (Nasdaq: TEVA) reports Q2 earnings of $0.65 per share, above the consensus of $0.64. Revenues came in at $2.82 billion, versus the consensus of $2.68 billion.
Related Categories
EarningsStocks Mentioned
-0.43Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
